IndieBio

IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.

Parikshit Sharma

Partner

Past deals in Medical Devices

VIAN Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Flore by Sun Genomics

Convertible Note in 2024
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Minutia

Seed Round in 2024
Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

OncoPrecision

Convertible Note in 2024
OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Chronus Health

Convertible Note in 2024
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Flore by Sun Genomics

Series B in 2023
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

RizLab Health

Convertible Note in 2023
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

BioAesthetics

Convertible Note in 2023
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte

Series A in 2023
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Aluna

Series B in 2022
Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Flore by Sun Genomics

Series B in 2022
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

BioSapien

Series A in 2022
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Melio

Seed Round in 2022
Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Kalia Health

Convertible Note in 2022
Kalia Health develops a safe, affordable, and accessible home-based early detection test to improve maternal health. The company was founded in 2019 and is based in Chapel Hill, North Carolina.

Kalia Health

Seed Round in 2022
Kalia Health develops a safe, affordable, and accessible home-based early detection test to improve maternal health. The company was founded in 2019 and is based in Chapel Hill, North Carolina.

Conan MedTech

Convertible Note in 2022
Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

Conan MedTech

Seed Round in 2022
Conan MedTech develops a rapid POC diagnostic test for concussions. The company aims to revolutionize the mild traumatic brain injury diagnosis market to allow sport medicine doctors and athletic coaches and trainers to make a decision on the sideline during a game. Conan MedTech was founded in 2020 and is based in Ithaca, New York.

QuantumCyte

Convertible Note in 2022
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Cellens

Seed Round in 2022
Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

OncoPrecision

Seed Round in 2021
OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

RizLab Health

Convertible Note in 2021
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

RizLab Health

Seed Round in 2021
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.

QuantumCyte

Convertible Note in 2021
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Chronus Health

Convertible Note in 2021
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Aluna

Series A in 2020
Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Cayuga

Pre Seed Round in 2020
Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Flore by Sun Genomics

Series A in 2020
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Chronus Health

Seed Round in 2020
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Flore by Sun Genomics

Convertible Note in 2019
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

BioAesthetics

Convertible Note in 2019
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte

Convertible Note in 2019
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Chronus Health

Seed Round in 2019
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Flore by Sun Genomics

Venture Round in 2019
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Clinicai

Seed Round in 2018
Clinicai is building a smart toilet monitor for non-invasive early detection of gastrointestinal cancers and diseases.

Chronus Health

Seed Round in 2018
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Mouth2Mouth

Seed Round in 2018
Mouth2Mouth is a healthcare startup that develops personalized probiotics for oral health. Based on microbiome data from thousands of healthy individuals, their AI-driven platform determines consortia of beneficial bacteria that fight widespread conditions such as tooth decay, gum disease, and bad breath. The company is on a mission to improve oral hygiene and provide a solution to oral diseases by use of an all-natural process.

QuantumCyte

Convertible Note in 2018
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Mezomax

Seed Round in 2017
MezoMax, Inc. is a biotechnology company based in San Francisco, California, founded in 2017. It specializes in developing oral therapies for nonhealing fractures and bone-related diseases, focusing on enhancing fracture healing and treating osteoporosis, particularly in elderly patients. The company’s innovative product features a novel calcium gluconate stereoisomer that regulates calcium and mineral metabolism, facilitating faster osteogenesis. By stimulating bone-forming cells, MezoMax's small molecule drug offers a safer and more effective approach to bone repair, enabling healthcare professionals to improve patient outcomes in the management of fractures and rare bone diseases.

Flore by Sun Genomics

Seed Round in 2017
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

NURO

Pre Seed Round in 2017
NURO is the manufacturer of the NUOS, PAD, KOMPOS and MENTIS surgery-free neurological platforms. For more information, please visit www.nuro.world.

BioAesthetics

Seed Round in 2017
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioAesthetics

Seed Round in 2017
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

QuantumCyte

Seed Round in 2017
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Senzo

Convertible Note in 2016
Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Aluna

Seed Round in 2016
Aluna is focused on empowering patients with chronic respiratory conditions, particularly asthma, by providing tools for better understanding and management of their lung health. The company has developed a portable spirometer device that utilizes machine learning and integrates with a mobile app. This technology allows patients to take daily measurements of their asthma, track symptoms, medication use, exercise, and environmental factors. By objectively monitoring asthma severity, the device enables healthcare providers to detect early signs of asthma attacks and create personalized, real-time action plans for their patients. Aluna is committed to enhancing the quality of life for individuals with asthma through innovative medical devices and healthcare solutions.

Senzo

Convertible Note in 2015
Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

V-Sense Medical

Pre Seed Round in 2015
There is a tangled mess of wires, electrode stickers and blood pressure cuffs in the ICUs, ERs and operating rooms of modern medical facilities. The design of these instruments presents many challenges which include patient safety and comfort, measurement accuracy and reliability, equipment sterilization or disposability, burdensome ancillary staff requirements, and most importantly delays in care during critical diagnostic and resuscitative efforts. V-Sense Medical Devices use NASA radar technology to monitor vital signs without any contact with the patient. It does not require wearables, leads, contacts, stickers, or wires. Please sign up to our newsletter to stay in touch, and check our news and blog pages!

Senzo

Convertible Note in 2015
Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Senzo

Seed Round in 2014
Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.